Latest & greatest articles for topiramate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on topiramate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on topiramate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for topiramate

41. Topiramate for migraine prevention: a randomized controlled trial. Full Text available with Trip Pro

Topiramate for migraine prevention: a randomized controlled trial. Small open-label and controlled trials suggest that the antiepileptic drug topiramate is effective for migraine prevention.To assess the efficacy and safety of topiramate for migraine prevention in a large controlled trial.A 26-week, randomized, double-blind, placebo-controlled study was conducted during outpatient treatment at 52 North American clinical centers. Patients were aged 12 to 65 years and had a 6-month history (...) of migraine (International Headache Society criteria) and 3 to 12 migraines a month but no more than 15 headache days a month during a 28-day prospective baseline phase.After a washout period, patients meeting entry criteria were randomized to topiramate (50, 100, or 200 mg/d) or placebo. Topiramate was titrated by 25 mg/wk for 8 weeks to the assigned or maximum tolerated dose, whichever was less. Patients continued receiving that dose for 18 weeks.The primary efficacy measure was change from baseline

2004 JAMA Controlled trial quality: predicted high

42. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. (Abstract)

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Topiramate, a sulphamate fructopyranose derivative, might antagonise alcohol's rewarding effects associated with abuse liability by inhibiting mesocorticolimbic dopamine release via the contemporaneous facilitation of gamma-amino-butyric acid activity and inhibition of glutamate function. We aimed to see whether topiramate was more effective than placebo as a treatment for alcohol dependence.We did a double (...) -blind randomised controlled 12-week clinical trial comparing oral topiramate and placebo for treatment of 150 individuals with alcohol dependence. Of these 150 individuals, 75 were assigned to receive topiramate (escalating dose of 25-300 mg per day) and 75 had placebo as an adjunct to weekly standardised medication compliance management. Primary efficacy variables were: self-reported drinking (drinks per day, drinks per drinking day, percentage of heavy drinking days, percentage of days abstinent

2003 Lancet Controlled trial quality: predicted high

43. Topiramate (Topamax) use in treating neuropathic pain

Topiramate (Topamax) use in treating neuropathic pain Topiramate (Topamax) use in treating neuropathic pain Topiramate (Topamax) use in treating neuropathic pain WCB Evidence Based Practice Group Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation WCB Evidence Based Practice Group. Topiramate (Topamax) use in treating neuropathic pain. Richmond, BC: WorkSafe BC 2003 (...) : 4 Authors' objectives This study reviews the use of topiramate (topamax) in treating neuropathic pain. Authors' conclusions To date, there is no high level evidence to support the efficacy of Topiramate in treating neuropathic pain. There is low level anecdotal evidence that suggests this medication may be beneficial in treating diabetic peripheral neuropathy and intercostal neuralgia. It is also worthwhile mentioning that, in general, there is very little information on this medication

2003 Health Technology Assessment (HTA) Database.

44. Topiramate: a review of its use in childhood epilepsy

Topiramate: a review of its use in childhood epilepsy Topiramate: a review of its use in childhood epilepsy Topiramate: a review of its use in childhood epilepsy Ormrod D, McClellan K Authors' objectives To review the use of topiramate in childhood epilepsy. Searching MEDLINE, EMBASE and AdisBase were searched to March 2001. The key terms were stated. The reference lists of published reports were examined and the pharmaceutical company who had developed the drug was contacted for further (...) published and unpublished data. Study selection Study designs of evaluations included in the review The inclusion criteria were not explicitly defined in terms of the study design. Double-blind randomised controlled trials (RCTs), with and without open extensions, and non-comparative studies (retrospective and prospective post-marketing studies) were used to assess treatment efficacy. Meta-analyses were also included. Specific interventions included in the review Studies of topiramate were eligible

2001 DARE.

45. Topiramate for drug-resistant partial epilepsy. (Abstract)

Topiramate for drug-resistant partial epilepsy. The majority of epileptic patients have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug-resistant partial epilepsy.To evaluate the efficacy and tolerability of topiramate (...) when used as an add-on treatment in patients with drug resistant partial epilepsy.(a) The Cochrane Library (1999 Issue 1); (b) The controlled trial register of the Cochrane Epilepsy Group; (c) Johnson and Johnson, makers of topiramate; (d) Experts in the field.Randomized placebo controlled add-on trials of topiramate in patients with drug resistant epilepsy.Two reviewers independently selected trials for inclusion and extracted the relevant data. The following outcomes were assessed: (a) 50

2000 Cochrane